Evidence map›Paper›PMID 29793358›Full record

Observational studyJournal of cardiovascular pharmacology and therapeutics2019

The Association Between β-Blocker Use and Cardiorespiratory Fitness: The Maastricht Study.

Johannes T H Nielen, Frank de Vries, Jeroen H P M van der Velde, Hans H C M Savelberg, Nicolaas C Schaper, Pieter C Dagnelie, Ronald M A Henry, Miranda Schram, Coen D A Stehouwer, Annelies Boonen and 2 more

Open access · hybridAbstract readComparative StudyObservational Study
In one paragraph

Observational study in Journal of cardiovascular pharmacology and therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Hypertrophic Cardiomyopathy: Updates Through the Lens of Sports Cardiology.Current treatment options in cardiovascular medicine · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Johannes T H Nielen1 Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0002-3633-2504
Frank de Vries1 Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, the Netherlands.
Jeroen H P M van der Velde5 Department of Human Movement Sciences, School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, the Netherlands.ORCID 0000-0002-2904-4598
Hans H C M Savelberg5 Department of Human Movement Sciences, School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, the Netherlands.
Nicolaas C Schaper3 School for Care and Public Health (CAPHRI), Maastricht University, Maastricht, the Netherlands.
Pieter C Dagnelie2 Department of Epidemiology, Maastricht University, Maastricht, the Netherlands.
Ronald M A Henry6 School for Cardiovascular Diseases (CARIM), Maastricht University, Maastricht, the Netherlands.
Miranda Schram6 School for Cardiovascular Diseases (CARIM), Maastricht University, Maastricht, the Netherlands.
Coen D A Stehouwer3 School for Care and Public Health (CAPHRI), Maastricht University, Maastricht, the Netherlands.
Annelies Boonen3 School for Care and Public Health (CAPHRI), Maastricht University, Maastricht, the Netherlands.
Annemarie Koster3 School for Care and Public Health (CAPHRI), Maastricht University, Maastricht, the Netherlands.
Bart J F van den Bemt4 Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center +, Maastricht, the Netherlands.
Maastricht University · NLMaastricht University Medical Centre · NLUtrecht University · NLRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeβ-Blockers (BBs) have been associated with a reduced cardiorespiratory fitness (CRF). This is possibly caused by inhibition of β2-receptors in the airways. However, there are limited data available on β-receptor selectivity and CRF. We therefore aimed to assess the association between BB use and CRF and to assess the association between β-receptor selectivity and CRF.

methodsParticipants in the Maastricht Study were aged between 40 and 75 years. Exposure to BB use was determined by use of pharmacy records. General linear models were used to obtain adjusted means of 2 proxies for CRF: covered distance during the 6-minute walk test (6MWT) and estimated maximum power output adjusted for body mass ( W

resultsCompared to never use, current use was associated with a lower CRF, based on the 6MWT (current use: 569.7 m; never use: 580.4 m [ P = .010]), but not based on the cycling test (current use: 2.14 W kg

conclusionβ-Blockers use was associated with CRF based on the 6MWT but not the cycling test. There was no difference between current selective and nonselective BB users, possibly due to the small number of nonselective BB users, differential underlying diseases, other pharmacological properties, and limitations related to the proxies of the outcome.

Indexed as

Cardiorespiratory FitnessAdrenergic beta-AntagonistsAdultAgedBicyclingExercise ToleranceFemaleHealth StatusHumansMaleMiddle AgedNetherlandsPredictive Value of TestsProspective StudiesTime FactorsWalk TestAdrenergic beta-Antagonistscardiorespiratory fitnesswork loadβ-blockers

Identifiers

PMID29793358
PMCPMC6297897
OpenAlexW2804527228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.